Schizophrenia Long-Term Treatment: What Phase 3 Studies Involve
Managing schizophrenia is often a long-term effort, and finding a treatment that works well isn't the end of the story — understanding how that treatment holds up over months and years matters just as much. That's the focus of a specific type of clinical trial: the long-term, open-label Phase 3 study.
What Makes a Long-Term Safety Study Different
By the time a treatment reaches Phase 3, it has already shown promise for effectively managing symptoms in earlier trials. This next stage looks at a different question: how safe and well-tolerated is the treatment when taken consistently over an extended period of time?
A study currently enrolling at Inner Space Research is evaluating the long-term safety and tolerability of an investigational treatment, NBI-1117568, in adults with schizophrenia. Unlike some trials that compare a treatment against a placebo, this is an open-label study — meaning every participant receives the actual investigational treatment, and both participants and the study team know what's being given. The focus here is on tracking how the treatment performs and is tolerated over time, not on comparing it to an inactive substance.
Every aspect of the study, including monitoring requirements and safety checks, is governed by a protocol reviewed and approved by an Institutional Review Board (IRB) before enrollment begins.
Who Might Qualify
Long-term schizophrenia studies typically look for adults who:
Have a diagnosis of schizophrenia and are currently managing their symptoms. Have participated in, or are eligible to transition from, an earlier related study, or otherwise meet the specific entry criteria for this trial. Are medically stable enough to participate in ongoing monitoring and visits over an extended period.
Because this is a long-term commitment, eligibility and fit are determined carefully through a full screening process — not a quick questionnaire.
What Screening Looks Like
If you're interested, the process usually starts with a conversation about your diagnosis, treatment history, and current symptoms. If you appear to be a good candidate, you'll come in for a complete clinical evaluation, which may include a diagnostic interview, physical exam, and lab work, to confirm you meet the study's requirements.
What Participation Involves
Because this is a long-term study, participation looks a bit different from a short-term trial. You can generally expect:
Regular visits with the study team over an extended period to monitor your symptoms and overall health. Ongoing safety assessments, including physical exams and lab work as specified by the protocol. Consistent access to the investigational treatment throughout the study, since it is open-label rather than placebo-controlled.
This structure gives researchers meaningful data about how a treatment performs in real-world, longer-term use — information that's just as important as a treatment's initial effectiveness.
What You Gain From Participating
Participants receive study-related care and monitoring at no cost, along with consistent, ongoing attention from a clinical team over the length of the study. You're also contributing directly to research that helps determine whether a treatment remains safe and effective for long-term use — information that matters for future patients managing schizophrenia.
Is This the Right Fit for You?
If you're an adult in the Orem, Utah area managing schizophrenia and interested in a long-term treatment study, our current study evaluating NBI-1117568 may be worth exploring. Reaching out starts with a conversation — no obligation, just information.
Learn more about our current schizophrenia study →
This article is for general educational purposes and is not a substitute for medical advice. Please consult your healthcare provider about your specific situation and treatment options.